Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Donepezil

Donepezil

Introduction

Donepezil is a centrally acting reversible acetylcholinesterase inhibitor, widely used in the management of Alzheimer’s disease (AD) and other cognitive impairments. Marketed under the brand name Aricept, Donepezil has emerged as one of the cornerstone drugs in dementia care. It is primarily indicated for mild to moderate Alzheimer’s disease but is also used off-label in other dementias.

Chemical and Pharmacological Profile

  • Chemical Name: (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride

  • Molecular Formula: C24H29NO3·HCl

  • Drug Class: Acetylcholinesterase inhibitor

  • ATC Code: N06DA02

Mechanism of Action

Donepezil functions by selectively and reversibly inhibiting the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine:

  • Cholinergic Hypothesis: Alzheimer’s disease is characterized by a deficit in cholinergic neurotransmission in the brain, particularly in the hippocampus and cortex.

  • Neurochemical Effect: By inhibiting acetylcholinesterase, Donepezil increases the concentration of acetylcholine in synaptic clefts, thereby enhancing cholinergic transmission.

  • Clinical Impact: This effect contributes to improved cognition, memory, and behavioral symptoms in patients with Alzheimer’s.

Pharmacokinetics

  • Absorption: Rapid and complete oral absorption; peak plasma levels in 3–4 hours

  • Bioavailability: Approximately 100%

  • Half-Life: 70 hours, allowing for once-daily dosing

  • Metabolism: Hepatic via CYP2D6 and CYP3A4

  • Excretion: Mainly via urine (57%) and feces (15%)

Clinical Uses

  1. Alzheimer’s Disease (Mild to Moderate): Donepezil is FDA-approved for this indication.

  2. Alzheimer’s Disease (Severe): Higher doses (23 mg) have shown modest benefit in severe cases.

  3. Lewy Body Dementia: Off-label use for cognitive and behavioral symptoms.

  4. Vascular Dementia: Limited efficacy; sometimes used based on clinician discretion.

  5. Parkinson’s Disease Dementia: Used cautiously to improve cognitive symptoms.

  6. Traumatic Brain Injury (TBI): Investigational use in cognitive rehabilitation.

Formulations and Dosage

  • Formulations: Tablets, orally disintegrating tablets (ODT), and extended-release tablets

  • Initial Dose: 5 mg once daily

  • Maintenance Dose: May be increased to 10 mg daily after 4–6 weeks

  • Maximum Dose: 23 mg once daily (for severe Alzheimer’s)

Efficacy in Clinical Trials

  • Mild to Moderate AD: Significant but modest improvements in cognitive scores (ADAS-Cog, MMSE)

  • Severe AD: The 23 mg formulation showed slightly better cognitive scores but increased side effects

  • Long-Term Use: Slows decline in cognition and function but does not halt disease progression

Adverse Effects

  • Common:

    • Nausea

    • Diarrhea

    • Insomnia

    • Muscle cramps

    • Fatigue

  • Serious:

    • Bradycardia and syncope

    • Gastrointestinal bleeding (especially in patients on NSAIDs)

    • Seizures (rare)

    • Rhabdomyolysis (very rare)

Drug Interactions

  • Anticholinergic Drugs: Oppose the action of Donepezil

  • CYP3A4/CYP2D6 Inhibitors (e.g., ketoconazole, quinidine): Increase plasma levels

  • CYP Inducers (e.g., phenytoin, carbamazepine): Decrease Donepezil efficacy

  • NSAIDs: Increased risk of GI bleeding

Contraindications and Precautions

  • Contraindications:

    • Hypersensitivity to Donepezil or piperidine derivatives

  • Caution In:

    • Peptic ulcer disease

    • Asthma or COPD

    • Bradycardia or conduction abnormalities

    • Urinary obstruction

Monitoring Parameters

  • Cognitive Function: MMSE, ADAS-Cog at baseline and regular intervals

  • Heart Rate and ECG: Especially in elderly or cardiac patients

  • GI Symptoms: Monitor for bleeding or signs of ulceration

Donepezil in Special Populations

  • Elderly: Primary target group; monitor cardiovascular effects

  • Renal Impairment: No dose adjustment needed

  • Hepatic Impairment: Use cautiously; monitor liver function tests

  • Pediatrics: Not recommended

  • Pregnancy and Lactation: Category C; use only if benefits outweigh risks

Comparison with Other Cholinesterase Inhibitors

  1. Rivastigmine:

    • Also inhibits butyrylcholinesterase

    • Available as patch for those with GI issues

  2. Galantamine:

    • Dual mechanism: AChE inhibition and allosteric modulation of nicotinic receptors

    • More GI side effects reported

  3. Tacrine:

    • First cholinesterase inhibitor; now obsolete due to hepatotoxicity

Patient Counseling Tips

  • Take once daily, preferably at bedtime to reduce nausea

  • Maintain hydration, especially during diarrhea or vomiting

  • Watch for dizziness or fainting—risk of falls

  • Regular follow-ups to assess effectiveness and side effects

Regulatory Status

  • FDA Approval: 1996 for mild to moderate AD, 2010 for severe AD

  • WHO Essential Medicines List: Included

  • Global Availability: Widely available as brand and generic

Future Developments

  • Combination Therapies: Donepezil + Memantine combinations under exploration

  • Neuroprotective Research: Investigating its effects beyond cholinesterase inhibition

  • Biomarker Studies: To tailor therapy based on genetic markers (e.g., ApoE4)

Common Myths and Facts

  • "Donepezil cures Alzheimer’s": FALSE. It only slows progression.

  • "Once memory improves, the drug can be stopped": FALSE. Discontinuation often leads to rapid decline.

  • "High doses are always more effective": FALSE. Higher doses increase side effects without proportional benefit.

Challenges in Use

  • Non-Responders: 30–40% of patients may show minimal clinical improvement

  • Adherence Issues: Due to side effects like nausea and GI distress

  • Cost Concerns: Especially for newer formulations or combination products

Conclusion

Donepezil remains one of the most widely prescribed agents in the management of Alzheimer’s disease. Though it offers only symptomatic relief and does not modify disease progression, its role in improving quality of life for patients and caregivers is significant. With ongoing research and evolving therapeutic strategies, Donepezil continues to be a critical component of dementia care. Its use requires careful monitoring, patient education, and a multidisciplinary approach to optimize outcomes.

References

  1. Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018.

  2. FDA Prescribing Information for Aricept

  3. Alzheimer's Association Clinical Guidelines

  4. WHO Model List of Essential Medicines

  5. Neurology and Psychiatry Journals on Alzheimer’s Disease